Payment overview · 2025
General Payments
$17.42
1 reported records · 1 companies
Healthcare provider profile · identity verified
Paul Daniel Miller, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · OAKLAND, MD · NPI 1194727487
Verified facts
What the public records show
CMS Open Payments records show Paul Daniel Miller, D.O. received $17.42 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.42 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.42 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
395 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
50 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 646 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 50 |
| Eliquis | Apixaban | 395 | 47 |
| Furosemide | Furosemide | 374 | 56 |
| Lisinopril | Lisinopril | 297 | 38 |
| Potassium Chloride | Potassium Chloride | 271 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 263 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 35 |
| Sertraline Hcl | Sertraline Hcl | 224 | 25 |
| Gabapentin | Gabapentin | 223 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 35 |
| Divalproex Sodium | Divalproex Sodium | 207 | 30 |
| Metformin Hcl | Metformin Hcl | 190 | 24 |
| Trazodone Hcl | Trazodone Hcl | 187 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 35 |
| Tramadol Hcl | Tramadol Hcl | 145 | 40 |
| Omeprazole | Omeprazole | 138 | 33 |
| Lorazepam | Lorazepam | 133 | 19 |
| Donepezil Hcl | Donepezil Hcl | 124 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 114 | 56 |
| Buspirone Hcl | Buspirone Hcl | 113 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 22 |
| Mirtazapine | Mirtazapine | 112 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 106 | 28 |
| Sodium Chloride | 0.9 % Sodium Chloride | 87 | 20 |
| Montelukast Sodium | Montelukast Sodium | 83 | 12 |
| Losartan Potassium | Losartan Potassium | 81 | 15 |
| Baclofen | Baclofen | 73 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 71 | 57 |
| Pregabalin | Pregabalin | 70 | suppressed |
| Allopurinol | Allopurinol | 67 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 21 |
| Risperidone | Risperidone | 67 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | suppressed |
| Sucralfate | Sucralfate | 63 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 62 | 28 |
| Memantine Hcl | Memantine Hcl | 62 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 61 | 14 |
| Alendronate Sodium | Alendronate Sodium | 59 | suppressed |
| Digoxin | Digoxin | 57 | suppressed |
| Atenolol | Atenolol | 56 | suppressed |
| Glipizide | Glipizide | 55 | suppressed |
| Prednisone | Prednisone | 55 | 29 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Carvedilol | Carvedilol | 54 | suppressed |
| Tradjenta | Linagliptin | 52 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 50 | 45 |
| Finasteride | Finasteride | 49 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Haloperidol | Haloperidol | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 20 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 13 |
| Nitroglycerin Patch | Nitroglycerin | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 17 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 35 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 20 |
| Enulose | Lactulose | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Lidocaine Hcl | Lidocaine Hcl | 28 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 14 |
| Anastrozole | Anastrozole | 25 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 25 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | 17 |
| Nyamyc | Nystatin | 24 | 17 |
| Simvastatin | Simvastatin | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Erythromycin | Erythromycin Base | 21 | 20 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Phenytoin | Phenytoin | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 13 |
| Budesonide Er | Budesonide | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 15 |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clonidine | Clonidine | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lorazepam Intensol | Lorazepam | 13 | 13 |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.42 · 1 records | PFIZER INC. | PAXLOVID | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error